June 6
Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we are
Vaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution
View ProjectDeveloping a new class of therapeutics that enhance the function of beneficial proteins
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectOur vision is to perform world-class medical research that focuses on the molecular basis of health and disease. The specific areas of our research include cancer, molecular bioscience, metabolic and musculoskeletal medicine, infection and immunity.
ViewWe conduct eye research with real-life impact. We are unravelling the causes of diseases, preventing blindness through earlier diagnosis and better treatments, and restoring sight.
ViewMater Research is a recognised leader in medical research. Our bench to bedside philosophy sees us working across Mater Health’s hospitals and health services, The University of Queensland, and the world-class Translational Research Institute (TRI).
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn more